NCT00084448终止2 期
A Phase II Evaluation of Weekly Paclitaxel (NSC #673089) and Celecoxib (Celebrex®, NSC #719627) in the Treatment of Recurrent or Persistent Platinum-Resistant Epithelial Ovarian or Primary Peritoneal Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 试验地点
- 1
- 主要终点
- Antitumor activity
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and may increase the effectiveness of paclitaxel by making tumor cells more sensitive to the drug. Giving celecoxib together with paclitaxel may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving paclitaxel together with celecoxib works in treating patients with recurrent or persistent platinum-resistant ovarian epithelial or primary peritoneal cancer.
详细描述
OBJECTIVES:
- Determine the antitumor activity of paclitaxel and celecoxib in patients with recurrent or persistent platinum-resistant ovarian epithelial or primary peritoneal cancer.
- Determine the nature and degree of toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and oral celecoxib twice daily on days 2-6, 9-13, and 16-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed ovarian epithelial or primary peritoneal cancer
- •Recurrent or persistent disease
- •Measurable disease
- •At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
- •At least 1 target lesion not in a previously irradiated field
- •Must have received 1 prior platinum-based chemotherapy regimen for primary disease containing carboplatin, cisplatin, or another organoplatinum compound
- •Initial treatment may have included high-dose therapy, consolidation, or extended therapy administered after surgical or non-surgical assessment
- •Platinum-resistant or refractory (i.e., had a treatment-free interval after platinum therapy of less than 6 months OR disease progression during platinum-based therapy)
- •Patients who have not received a prior taxane may have received a second regimen that included paclitaxel or docetaxel
- •Must not be eligible for a higher priority GOG protocol
- •PATIENT CHARACTERISTICS:
- •Not specified
- •Performance status
- •Life expectancy
- •Not specified
- •Hematopoietic
- •Absolute neutrophil count ≥ 1,500/mm^3
- •Platelet count ≥ 100,000/mm^3
- •SGOT ≤ 2.5 times upper limit of normal (ULN)
- •Alkaline phosphatase ≤ 2.5 times ULN
- •Bilirubin ≤ 1.5 times ULN
- •Creatinine ≤ 1.5 times ULN
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No active infection requiring antibiotics
- •No neuropathy (sensory and motor) > grade 1
- •No history of peptic ulcer disease
- •No allergies to sulfa or non-steroidal anti-inflammatory drugs
- •No known hypersensitivity to paclitaxel or celecoxib
- •No other invasive malignancy within the past 5 years except non-melanoma skin cancer
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •At least 3 weeks since prior biologic or immunologic therapy
- •One prior non-cytotoxic* regimen for recurrent or persistent disease allowed NOTE: *Non-cytotoxic (biologic or cytostatic) agents include (but are not limited to) monoclonal antibodies, cytokines, and small-molecule inhibitors of signal transduction
- •Chemotherapy
- •See Disease Characteristics
- •Recovered from prior chemotherapy
- •No other prior cytotoxic chemotherapy for recurrent or persistent disease, including retreatment with initial chemotherapy regimen
- •Endocrine therapy
- •At least 1 week since prior hormonal therapy for malignant tumor
- •Concurrent hormone replacement therapy allowed
- •Radiotherapy
- •See Disease Characteristics
- •Recovered from prior radiotherapy
- •No prior radiotherapy to more than 25% of marrow-bearing areas
- •See Disease Characteristics
- •Recovered from prior surgery
- •At least 3 weeks since prior therapy for malignant tumor
- 另有 3 项未显示
排除标准
- 未提供
结局指标
主要结局
Antitumor activity
Toxicity
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal CancerPrimary Peritoneal Cavity CancerOvarian CancerNCT00023907Gynecologic Oncology Group
Unknown
2 期
Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung CancerLung CancerNCT00004265University of Wisconsin, Madison
已完成
2 期
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate CancerProstate CancerNCT00003614Eastern Cooperative Oncology Group
已完成
2 期
Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian CancerOvarian CancerNCT00002928Memorial Sloan Kettering Cancer Center
撤回
1 期
Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00009828University of Pittsburgh